BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32753091)

  • 1. Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission.
    Patel A; Agha M; Raptis A; Hou JZ; Farah R; Redner RL; Im A; Dorritie KA; Sehgal A; Rossetti J; Saul M; Normolle D; Lontos K; Boyiadzis M
    Oncol Res; 2021 Sep; 28(7):811-814. PubMed ID: 32753091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
    Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.
    Weisdorf DJ; Millard HR; Horowitz MM; Hyare PS; Champlin R; Ho V; Mielcarek M; Rezvani A; Stockerl-Goldstein K; Khoury HJ; De Lima M; Saber W; Sandmaier B; Zhang MJ; Eapen M
    Cancer; 2017 Jun; 123(11):2025-2034. PubMed ID: 28117884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
    Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
    Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission.
    Lv M; Wang Y; Chang YJ; Zhang XH; Xu LP; Jiang Q; Jiang H; Lu J; Chen H; Han W; Wang FR; Wang JZ; Chen Y; Yan CH; Zhang YY; Sun YQ; Mo XD; Zhu HH; Jia JS; Zhao T; Wang J; Liu KY; Huang XJ
    Clin Cancer Res; 2019 Mar; 25(6):1737-1748. PubMed ID: 30478089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome.
    Verma D; Kantarjian H; Faderl S; O'Brien S; Pierce S; Vu K; Freireich E; Keating M; Cortes J; Ravandi F
    Leuk Lymphoma; 2010 May; 51(5):778-82. PubMed ID: 20196624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.
    Stahl M; DeVeaux M; Montesinos P; Itzykson R; Ritchie EK; Sekeres MA; Barnard JD; Podoltsev NA; Brunner AM; Komrokji RS; Bhatt VR; Al-Kali A; Cluzeau T; Santini V; Fathi AT; Roboz GJ; Fenaux P; Litzow MR; Perreault S; Kim TK; Prebet T; Vey N; Verma V; Germing U; Bergua JM; Serrano J; Gore SD; Zeidan AM
    Blood Adv; 2018 Apr; 2(8):923-932. PubMed ID: 29685952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission.
    Damiani D; Tiribelli M; Geromin A; Cerno M; Zanini F; Michelutti A; Fanin R
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1621-1626. PubMed ID: 27178373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
    Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
    Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy.
    Lim SJ; Lim MJ; Raptis A; Hou JZ; Farah R; Marks SM; Im A; Dorritie K; Sehgal A; Agha M; Felgar R; Lim SH
    Am J Hematol; 2015 Aug; 90(8):715-8. PubMed ID: 26010177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis.
    Helbig G; Koclęga A; Woźniczka K; Kopera M; Kyrcz-Krzemień S
    Pathol Oncol Res; 2018 Jul; 24(3):469-475. PubMed ID: 28660547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study.
    Østgård LSG; Lund JL; Nørgaard JM; Nørgaard M; Medeiros BC; Nielsen B; Nielsen OJ; Overgaard UM; Kallenbach M; Marcher CW; Riis AH; Sengeløv H
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):314-323. PubMed ID: 29051022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.
    DeZern AE; Sung A; Kim S; Smith BD; Karp JE; Gore SD; Jones RJ; Fuchs E; Luznik L; McDevitt M; Levis M
    Biol Blood Marrow Transplant; 2011 Sep; 17(9):1404-9. PubMed ID: 21324374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
    Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.
    Michelis FV; Messner HA; Atenafu EG; Kim DD; Kuruvilla J; Lipton JH; Uhm J; Loach D; Gupta V
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):474-9. PubMed ID: 24345422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.